Drugs / BAY2862789
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05858164 | Aug 2023 → Sep 2025 | non-small cell lung carcinoma | Bayer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2862789 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05858164 ↗ |
| Action | Inhibit | “BAY2862789 works by blocking an enzyme in T-cells, thereby activating them.” NCT05858164 ↗ |
| Route | Oral | “Oral administration, solution or tablets” NCT05858164 ↗ |